Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$7.62 USD
+0.20 (2.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VYGR 7.62 +0.20(2.70%)
Will VYGR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
Other News for VYGR
Commit To Purchase Voyager Therapeutics At $5, Earn 12.4% Annualized Using Options
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager announces selection of development candidate for GBA1 Program